These IDH mutations lead to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG), which promotes tumor initiation and progressive growth, and they are the target of new therapy for oligodendroglioma and of IDH-mutant gliomas [9]. This evidence concerns the gene IDH1 and central nervous system cancer.